HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

elaidic acid-cytarabine

a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine

Also Known As:

P-4055

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 06/15/1999 - "The antineoplastic efficacy of P-4055, a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine, a nucleoside antimetabolite frequently used in the treatment of hematological malignancies, was examined in several in vivo models for human cancer. "
2.	Neoplasms (Cancer) 06/15/1999 - "P-4055 induced partial or complete tumor regression of the lung carcinoma, as well as of all three malignant melanomas. " 06/15/1999 - "In two of the melanomas the activity was highly superior to that of cytarabine, and both P-4055 and cytarabine were, in general, more effective than several clinically established drugs previously tested in the same tumor models. " 06/15/1999 - "xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. " 06/15/1999 - "The antineoplastic efficacy of P-4055, a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine, a nucleoside antimetabolite frequently used in the treatment of hematological malignancies, was examined in several in vivo models for human cancer. "
3.	Meningeal Carcinomatosis 06/15/1999 - "In a Raji Burkitt's lymphoma leptomeningeal carcinomatosis model in nude rats, the control cytarabine- and saline-treated animals (five in each group) had a mean survival time of 13.2 days, whereas treatment with P-4055 resulted in three of five long-time survivors (>70 days). "
4.	Osteosarcoma (Osteogenic Sarcoma) 06/15/1999 - "xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. "
5.	Melanoma (Melanoma, Malignant) 06/15/1999 - "P-4055 induced partial or complete tumor regression of the lung carcinoma, as well as of all three malignant melanomas. " 06/15/1999 - "In two of the melanomas the activity was highly superior to that of cytarabine, and both P-4055 and cytarabine were, in general, more effective than several clinically established drugs previously tested in the same tumor models. " 06/15/1999 - "xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. "

Related Drugs and Biologics

1.	Nucleosides
2.	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
3.	Esters
4.	Cytarabine (Cytosar-U)
5.	Antineoplastic Agents (Antineoplastics)
6.	Antimetabolites
7.	Acids

Related Therapies and Procedures

1.	Injections